Table 4 The GO annotation showing the terms related to KEGG pathways that were enriched in arsenic–protein interactome dataset
Pathway ID | KEGG pathway description | False discovery rate |
|---|---|---|
5200 | Pathways in cancer | 5.97E−17 |
5206 | MicroRNAs in cancer | 5.97E−17 |
5212 | Pancreatic cancer | 2.41E−16 |
5205 | Proteoglycans in cancer | 1.90E−15 |
5219 | Bladder cancer | 9.76E−14 |
5161 | Hepatitis B | 3.40E−13 |
4068 | FoxO signaling pathway | 1.09E−12 |
5210 | Colorectal cancer | 6.97E−12 |
4066 | HIF-1 signaling pathway | 1.06E−10 |
5223 | Non-small cell lung cancer | 1.54E−10 |
4917 | Prolactin signaling pathway | 1.40E−09 |
4668 | TNF signaling pathway | 2.81E−09 |
4932 | Non-alcoholic fatty liver disease (NAFLD) | 3.65E−09 |
5215 | Prostate cancer | 7.50E−09 |
4370 | VEGF signaling pathway | 9.18E−09 |
4915 | Estrogen signaling pathway | 1.48E−08 |
5203 | Viral carcinogenesis | 2.58E−08 |
5145 | Toxoplasmosis | 6.98E−08 |
5213 | Endometrial cancer | 7.34E−08 |
4012 | ErbB signaling pathway | 1.11E−07 |
4151 | PI3K–Akt signaling pathway | 1.53E−07 |
5152 | Tuberculosis | 1.57E−07 |
4150 | mTOR signaling pathway | 2.00E−07 |
5214 | Glioma | 2.43E−07 |
4115 | p53 signaling pathway | 4.08E−07 |
2010 | ABC transporters | 4.61E−07 |
4010 | MAPK signaling pathway | 4.81E−07 |
5218 | Melanoma | 4.81E−07 |
5220 | Chronic myeloid leukemia | 4.81E−07 |
4510 | Focal adhesion | 5.94E−07 |